Ligand Pharmaceuticals IncNASDAQ:LGND
- LAST PRICE110.1000
- TODAY'S CHANGE (%)0.0600 (0.0545%)
- Bid / Lots109.7800/ 8
- Ask / Lots110.4100/ 8
- Open / Previous Close109.1400 / 110.0400
- Day Range
- 52 Week Range
- Volume24,314
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LGND |
|---|---|---|
| 09:32 ET | 901 | 109.14 |
| 09:35 ET | 100 | 108.505 |
| 09:39 ET | 300 | 108.5 |
| 09:50 ET | 208 | 108.38 |
| 09:57 ET | 100 | 108.37 |
| 10:00 ET | 100 | 108.59 |
| 10:02 ET | 100 | 109.135 |
| 10:04 ET | 3035 | 108.11 |
| 10:06 ET | 100 | 108.485 |
| 10:08 ET | 200 | 108.545 |
| 10:09 ET | 100 | 109.17 |
| 10:18 ET | 200 | 109.285 |
| 10:20 ET | 100 | 109.435 |
| 10:26 ET | 100 | 109.45 |
| 10:27 ET | 2602 | 110.02 |
| 10:31 ET | 100 | 110.2 |
| 10:33 ET | 813 | 110.28 |
| 10:38 ET | 100 | 110.325 |
| 10:42 ET | 100 | 110.315 |
| 10:51 ET | 442 | 110.445 |
| 10:54 ET | 100 | 110.445 |
| 11:00 ET | 500 | 110.2 |
| 11:02 ET | 100 | 109.95 |
| 11:07 ET | 206 | 109.53 |
| 11:12 ET | 200 | 109.955 |
| 11:18 ET | 100 | 110.37 |
| 11:20 ET | 100 | 109.98 |
| 11:21 ET | 100 | 110.095 |
| 11:25 ET | 200 | 110.125 |
| 11:27 ET | 100 | 110.13 |
| 11:34 ET | 200 | 110.045 |
| 11:41 ET | 100 | 109.625 |
| 11:43 ET | 200 | 109.7 |
| 11:50 ET | 100 | 109.34 |
| 12:01 ET | 450 | 109.45 |
| 12:21 ET | 200 | 109.505 |
| 12:24 ET | 206 | 109.72 |
| 12:30 ET | 400 | 110.1 |
Nov 1, 2024
Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston, from 8:01AM ET on Friday Nov 01, 2024 by Dow Jones
8:01AM ET on Friday Nov 01, 2024 by Dow Jones
Oct 31, 2024
DJ Ligand Pharmaceuticals Price Target Maintained With a $157.00/Share by HC Wainwright & Co., from 10:18AM ET on Thursday Oct 31, 2024 by Dow Jones
10:18AM ET on Thursday Oct 31, 2024 by Dow Jones
Oct 28, 2024
DJ Ligand Pharmaceuticals Is Maintained at Overweight by Barclays, from 10:14AM ET on Monday Oct 28, 2024 by Dow Jones
10:14AM ET on Monday Oct 28, 2024 by Dow Jones
Oct 23, 2024
Press Release: Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024, from 5:11PM ET on Wednesday Oct 23, 2024 by Dow Jones
5:11PM ET on Wednesday Oct 23, 2024 by Dow JonesLigand to Report Third Quarter 2024 Financial Results on November 7, 2024, from 4:01PM ET on Wednesday Oct 23, 2024 by Dow Jones
4:01PM ET on Wednesday Oct 23, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ligand Pharmaceuticals Inc | 2.0B | 49.5x | -12.71% |
Harrow Inc | 1.6B | -48.6x | --- |
Ocular Therapeutix Inc | 1.6B | -9.6x | --- |
Immunocore Holdings PLC | 1.6B | -29.3x | --- |
Avadel Pharmaceuticals PLC | 1.4B | -12.8x | --- |
Evolus Inc | 1.1B | -18.1x | --- |
Company Information
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
Contact Information
- Headquarters
- 555 Heritage Drive, Suite 200JUPITER, FL, United States 33458
- Phone
- 858-550-7500
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- John Kozarich
- Chief Executive Officer, Director
- Todd Davis
- Chief Financial Officer
- Octavio Espinoza
- Chief Legal Officer
- Andrew Reardon
- Independent Director
- Jason Aryeh
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.0B |
|---|---|
Revenue (TTM) | $133.5M |
Shares Outstanding | 18.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.03 |
EPS | $2.22 |
Book Value | $39.92 |
P/E Ratio | 49.5x |
Price/Sales (TTM) | 15.1 |
Price/Cash Flow (TTM) | 26.0x |
Operating Margin | -14.53% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
